What is Ancora Holdings' main argument for why Ashland should be sold?

Ancora Holdings argues that a sale is 'the best path to realizing Ashland’s intrinsic value in the face of the company’s significant trading discount and near-term growth and execution issues,' citing Ashland’s shares trading at a 'conglomerate discount' despite being a pure-play specialty chemicals company, its current EBITDA multiple of 9.6x (below its historical median of 11.0x), and its failure to deliver volume growth under CEO Guillermo Novo’s investment-led organic growth strategy — having missed consensus estimates in four of the last five quarters.

Who are the potential acquirers of Ashland identified by Ancora, and what evidence does it cite for their interest?

Ancora identifies Standard Investments LLC (the investment arm of Standard Industries, which acquired W.R. Grace in 2021) as a 'logical buyer' with a history of accumulating small stakes before taking companies private; it also lists private equity firms Clayton, Dubilier & Rice (CD&R) and Advent International, and specialty chemical makers Croda and Nouryon as prospective buyers — though it explicitly states it 'did not specify whether any of these entities had expressed a meaningful interest in acquiring the company,' and notes only that its due diligence found Ashland has attracted 'meaningful interest … from other potential strategic acquirers and sponsors.'

Activist Investor Ancora Calls for Sale of Ashland

Jun 10, 2026

Activist investor Ancora Holdings urges Ashland Inc., a specialty chemicals firm, to pursue a sale valued at $4.5 billion due to undervaluation. Potential buyers include Croda and Nouryon, while Ancora threatens a proxy contest if management fails to act.

chemweek

Activist Investor Ancora Calls for Sale of Ashland

chemweek

2026-04-30

Ashland earnings dip on operational issues despite resilient demand

2026-06-09

Activist Ancora Builds Stake in Ashland, Pushes for Sale

2026-06-10

Activist Investor Ancora Calls for Sale of Ashland

2026-07-29

Ashland Q3 sales rise 7%, trims EPS outlook on tax rate